Zacks Research Analysts Decrease Earnings Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities researchers at Zacks Research lowered their FY2026 earnings per share estimates for Esperion Therapeutics in a research report issued on Monday, May 6th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings of $1.44 per share for the year, down from their prior estimate of $1.81. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.68) per share.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.03. The company had revenue of $32.25 million during the quarter, compared to the consensus estimate of $26.84 million. During the same period last year, the firm posted ($0.76) earnings per share.

A number of other equities analysts also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research note on Wednesday. Needham & Company LLC restated a “buy” rating and issued a $8.00 target price on shares of Esperion Therapeutics in a research note on Tuesday. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Esperion Therapeutics presently has an average rating of “Hold” and an average target price of $9.33.

Esperion Therapeutics Stock Down 13.9 %

Shares of NASDAQ:ESPR opened at $2.04 on Wednesday. The stock’s 50 day moving average is $2.31 and its 200-day moving average is $2.07. Esperion Therapeutics has a twelve month low of $0.70 and a twelve month high of $3.40. The firm has a market capitalization of $386.38 million, a price-to-earnings ratio of -0.96 and a beta of 0.89.

Institutional Trading of Esperion Therapeutics

Hedge funds have recently made changes to their positions in the company. Chicago Partners Investment Group LLC bought a new position in shares of Esperion Therapeutics in the third quarter worth $29,000. Jacob Asset Management of New York LLC purchased a new stake in Esperion Therapeutics in the third quarter worth approximately $59,000. Monaco Asset Management SAM raised its stake in shares of Esperion Therapeutics by 68.5% during the third quarter. Monaco Asset Management SAM now owns 1,171,779 shares of the biopharmaceutical company’s stock worth $1,148,000 after acquiring an additional 476,477 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of Esperion Therapeutics in the 3rd quarter worth approximately $131,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Esperion Therapeutics by 120.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 413,704 shares of the biopharmaceutical company’s stock valued at $405,000 after purchasing an additional 225,767 shares during the last quarter. 47.39% of the stock is currently owned by institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.